Status:
COMPLETED
TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborating Sponsors:
University of KwaZulu
Columbia University
Conditions:
Multi-drug Resistant Tuberculosis
Extensively Drug Resistant Tuberculosis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The antibiotic linezolid when given for the treatment of multi-drug resistant tuberculosis is safe and tolerated at a low dose (600 mg daily) for a limited duration (16 weeks)
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Pulmonary tuberculosis with or without extrapulmonary TB with a M. tuberculosis isolate that is confirmed to be resistant to at least rifampin and isoniazid (without regard to prior treatment for TB).
- A documented positive sputum culture result for M. tuberculosis from a sputum obtained in the four months prior to enrollment.
- Willingness to have HIV testing performed, if HIV serostatus is not known or if the last documented negative HIV test was more than 6 months prior to enrollment.
- Residence within the Durban Functional Region (Durban Metropolitan Area) or Tugela Ferry, Msinga District, KZN, RSA.
- Age ≥ 18 years.
- Karnofsky score of \> 50 (see section 18.1)
- Willingness by the patient to attend scheduled follow-up visits and undergo study assessments.
- Women with child-bearing potential must agree to practice an adequate method of birth control or to abstain from heterosexual intercourse during study therapy. (Standard birth control measures are provided free of charge by public health institutions)
- Laboratory parameters done within 14 days prior to screening:
- Serum creatinine level \< 2 times upper limit of normal
- Hemoglobin level ≥ 9.0 g/dL
- Platelet count of ≥ 80,000/mm3
- Absolute neutrophil count (ANC) \> 1000/ mm3
- Negative pregnancy test (for women of childbearing potential)
- Able to provide informed consent or legally authorized representative able to do so if decisionally impaired.
- Exclusion Criteria
- Currently breast-feeding or pregnant.
- Known allergy or intolerance to linezolid.
- Planned therapy during the intensive phase of tuberculosis treatment using drugs having unacceptable interactions with linezolid, including dopamine, selective serotonin uptake inhibitors (citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), amitriptyline, bupropion, mirtazepine, levodopa, carbidopa, sinemet, or herbal medications.
- Significant peripheral neuropathy as evidenced by \< 5 seconds of vibratory sense to a 128 Hz tuning fork on either big toe
- Pain, aching or burning of the feet that interfere with walking or sleep.
- In the judgment of the physician the patient is not expected to survive for more than 4 weeks.
- Anticipated surgical intervention for the treatment of pulmonary tuberculosis
- Visual acuity of 20/200 (6/60 meters) best corrected vision or less.
- Poor color vision as evidenced by incorrect answers on \> four of 12 screening Ishihara plates
- Participation in another drug trial.
- The patient has received second line TB drugs for \> 7 days immediately prior to enrollment (note: use of first line drugs such as INH, Rifampin, PZA, or ethambutol for \> 7 days immediately prior to enrollment is allowed)
Exclusion
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00664313
Start Date
April 1 2009
End Date
September 1 2010
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King George V Hospital
Durban, South Africa